The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." In late 2016, Benchmark Litigation named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."For more information about Lieff Cabraser and the firm's representation of investors, please visit http://www.lieffcabraser.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Envision Healthcare Corporation ("Envision" or the "Company") (NYSE: EVHC) between March 2, 2015 and July 21, 2017, inclusive (the "Class Period"). If you purchased or otherwise acquired Envision securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than October 3, 2017. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions. Envision investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358. Background on the Envision Securities Class Litigation Envision, based in Nashville, Tennessee, through its subsidiary EmCare Holdings, Inc. ("EmCare"), is one of the largest physician staffing companies for hospital emergency rooms in the United States. The action alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) EmCare routinely engaged in "surprise billing," whereby EmCare arranged for patients seeking treatment at in-network facilities to be treated by out-of-network physicians, and subsequently charged significantly higher billing rates; (ii) for this reason, the Company's statements during the Class Period attributing EmCare's growth to other factors were false and/or misleading; and (iii) Envision's revenues from EmCare were not be sustainable. On July 24, 2017, The New York Times reported that a study conducted by researchers at Yale University found that hospital emergency rooms run by EmCare were much more likely to engage in surprise billing. According to the Times, out of a sample of 194 hospitals emergency rooms run by EmCare, for example, the study found an average out-of-network billing rate of 62%, far higher than the national average. On this news, the price of Envision common stock fell $2.33 per share, or 3.72%, to close at $60.28 per share on July 24, 2017, on elevated trading volume. About Lieff Cabraser Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Seattle, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.